SEARCH

SEARCH BY CITATION

References

  • Bornhäuser, M., Illmer, T., Schaich, M., Soucek, S., Ehninger, G. & Thiede, C. (2007) Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood, 109, 22642265, author reply 2265.
  • Cooper, T.M., Franklin, J., Gerbing, R.B., Alonzo, T.A., Hurwitz, C., Raimondi, S.C., Hirsch, B., Smith, F.O., Mathew, P., Arceci, R.J., Feusner, J., Iannone, R., Lavey, R.S., Meshinchi, S. & Gamis, A.S. (2012) AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer, 118, 761769.
  • Gamis, A.S., Alonzo, T.A., Gerbing, R.B., Aplenc, R., Sung, L., Meshinchi, S., Raimondi, S.C., Hirsch, B.A., Kahwash, S., Heerema-McKenney, A., Winter, L., Glick, K., Byron, P., Burden, L., Wallas, T., Davies, S.M. & Smith, F.O. (2010) Remission rates in childhood acute myeloid leukemia (AML) utilizing a dose-intensive induction regimen with or without gemtuzumab ozogamicin (GO): initial results from the Children's Oncology Group phase III trial, AAML0531Blood (ASH Annual Meeting Abstracts), 116, 182.
  • Harrison, C.J., Hills, R.K., Moorman, A.V., Grimwade, D.J., Hann, I., Webb, D.K., Wheatley, K., deGraaf, S.S., van den Berg, E., Burnett, A.K. & Gibson, B.E. (2010) Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment Trials AML10 and 12. Journal of Clinical Oncology, 1, 26742681.
  • Ishiyama, K., Takami, A., Kanda, Y., Nakao, S., Maeda, T., Naoe, T., Tanigcuhi, S., Kawa, K., Nagamura, T., Tabuchi, K., Atsuta, Y. & Sakamaki, H. (2012) Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant. Leukemia, 26, 14161419.
  • Kalbfleish, J.D. & Prentice, R.L. (1980) The Statistical Analysis of Failure Time Data. John Wileve & Sons, New York.
  • Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457481.
  • Lange, B.J., Gerbing, R.B., Feusner, J., Skolnik, J., Sacks, N., Smith, F.O. & Alonzo, T.A. (2005) Mortality in overweight and underweight children with acute myeloid leukemia. Journal of the American Medical Association, 293, 203211.
  • Meshinchi, S., Woods, W.G., Stirewalt, D.L., Sweetser, D.A., Buckley, J.D., Tjoa, T.K., Bernstein, I.D. & Radich, J.P. (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood, 97, 8994.
  • Meshinchi, S., Alonzo, T.A., Stirewalt, D.L., Zwaan, M., Zimmerman, M., Reinhardt, D., Kaspers, G.J.L., Heerema, N.A., Gerbing, R., Lange, B.J. & Radich, J.P. (2006) Clinical implications of FLT3 mutations in pediatric AML. Blood, 108, 36543661.
  • Ravindranath, Y., Chang, M., Steuber, C.P., Becton, D., Dahl, G., Civin, C., Camitta, B., Carroll, A., Raimondi, S.C. & Weinstein, H.J. (2005) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia, 19, 21012116.
  • Schwartz, S., Jiji, R., Kerman, S., Meekins, J. & Cohen, M.M. (1983) Translocation (6;9)(p23;q34) in acute nonlymphocytic leukemia. Cancer Genetics and Cytogenetics, 10, 133138.
  • Slovak, M.L., Gundacker, H., Bloomfield, C.D., Dewald, G., Appelbaum, F.R., Larson, R.A., Tallman, M.S., Bennett, J.M., Stirewalt, D.L., Meshinchi, S., Wilman, C.L., Ravindranath, Y., Alonzo, T.A., Carroll, A.J., Raimondi, S.C. & Heerema, N.A. (2006) A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies. Leukemia, 20, 12951297.
  • Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., Ehninger, G. & Ilmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 43264335.
  • Woods, W.G., Kobrinsky, N., Buckley, J.D., Lee, J.A., Sanders, J., Neudorf, S., Gold, S., Barnard, D.R., SeSwarte, J., Dusenbery, K., Kalousek, D., Arthur, D.C. & Lange, B.J. (1996) Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood, 87, 49794989.